JEUVEAU
Peakprabotulinum toxin type a
BLAINJECTIONINJECTABLE
Approved
Feb 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
JEUVEAU (prabotulinum toxin type a) is acetylcholine release inhibitors [moa]. First approved in 2019.
Drug data last refreshed 17h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JEUVEAU is a botulinum toxin type A injectable approved by the FDA in February 2019 for cosmetic use in treating facial wrinkles and frown lines. It works by inhibiting acetylcholine release at the neuromuscular junction, causing temporary muscle relaxation. The product competes in the neuromodulator market alongside established players like BOTOX and DYSPORT.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30/100), suggesting stable but competitive revenue streams and established but not expanding field teams.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
JEUVEAU is a peak-stage cosmetic product with no dedicated job postings currently linked, reflecting a mature and stable team structure rather than active expansion. Professionals joining this product would focus on defending market share and optimizing existing commercial operations in a competitive neuromodulator landscape.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.